診斷放射性藥物和造影劑市場：按放射性藥物、造影劑和地區分類

預計到 2026 年，診斷放射性藥物和造影劑市場規模將達到 80.813 億美元，到 2033 年將達到 121.513 億美元。預計 2026 年至 2033 年的複合年成長率為 6.0%。

放射性藥物用於對目標器官或組織進行成像；這個過程稱為閃爍顯像。另一方面，造影劑用於成像技術中，以突出顯示影像中不同組織之間的差異。這些物質用於醫學成像，以增強體內結構和體液的對比。

市場動態：

心血管疾病的日益流行、癌症負擔的加重、診斷中心數量的增加、對影像引導手術和診斷的需求不斷成長，以及對診斷用放射性藥物和造影劑的需求不斷成長，預計這些因素將推動全球診斷用放射性藥物和造影劑市場的成長。

例如，2022年10月，Duchem Bio宣佈在韓國推出FACBC，這是全球首個用於診斷前列腺癌患者的放射性藥物。該藥物由日本製藥公司Mediphysics Japan研發，用於前列腺癌治療後血液中前列腺特異性抗原（PSA）水平升高的患者進行正電子發射斷層掃描（PET），以檢測前列腺癌可能復發的情況。

本研究的主要特點：

• 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
• 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
• 本研究根據公司概況、產品系列、主要亮點、財務表現和策略等參數，介紹了全球診斷放射性藥物和造影劑市場主要參與者的概況。
• 本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品類型升級、市場擴張和行銷策略做出明智的決策。
• 這份《全球診斷放射性藥物和造影劑市場》報告旨在為產業內的各類相關人員提供參考，包括經銷商、供應商、產品製造商、經銷商、新參與企業和金融分析師。
• 相關人員可以透過利用分析全球診斷放射性藥物和造影劑市場中使用的各種策略矩陣來簡化決策過程。

目錄

第1章：研究目標與前提條件

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章：市場動態、監管與趨勢分析

• 市場動態
  • 全球心血管疾病和癌症負擔日益加重。
  • 放射性藥物半衰期短和檢測技術成本高是造成這種情況的原因。
  • 對影像導引手術和診斷的需求日益成長
• 影響分析
• 主要亮點
• 監管趨勢
• 產品上市及核准
• PEST分析
• 波特五力分析
• 併購情景

第4章：全球診斷放射性藥物和造影劑市場

• 供給面和需求面分析
• 經濟影響

第5章 全球診斷放射性藥物和造影劑市場：以放射性藥物分類，2021-2033年

• 透過影像診斷方法
• 透過使用

第6章 全球診斷放射性藥物和造影劑市場：依造影劑類型分類，2021-2033年

• 通過測試
• 透過使用

第7章 全球診斷放射性藥物和造影劑市場：按地區分類，2021-2033年

• 北美洲
• 歐洲
• 亞太地區
• 拉丁美洲
• 中東和非洲

第8章 競爭情勢

• Siemens Healthineers
• Nordion Inc.
• Lantheus Holdings Inc.
• Guerbet Group
• GE Healthcare
• Curium
• Bracco Imaging SpA
• Bayer AG
• NTP Radioisotopes SOC Ltd.
• Cardinal Health Inc.

第9章

• 調查方法
• 關於本公司

Diagnostic Radiopharmaceuticals And Contrast Media Market is estimated to be valued at USD 8,081.3 Mn in 2026 and is expected to reach USD 12,151.3 Mn by 2033, growing at a compound annual growth rate (CAGR) of 6.0% from 2026 to 2033.

Radiopharmaceuticals are used to produce images of organs or tissues of interest, a process that is called scintigraphy. While, contrast media is used in imaging techniques to enhance the differences between body tissues on images. It is a substance used to increase the contrast of structures/fluids within the body in medical imaging.

Market Dynamics:

Increase in prevalence of cardiovascular diseases, rise in burden of cancer, increasing number of diagnostic centres, increasing demand for image-guided procedures and diagnostics, and increase in demand for diagnostic radiopharmaceuticals and contrast media, are major factors expected to propel growth of the global diagnostic radiopharmaceuticals and contrast media market.

For instance, in October 2022, Duchem Bio announced the launched of FACBC, the world's first radiopharmaceutical used when diagnosing prostate cancer patients, in Korea. The drug, developed by Nihon Medi Physics, a Japanese pharmaceutical company, is used when conducting positron emission tomography (PET) in patients suspected of having prostate cancer recurrence due to an increase in the prostate-specific antigen (PSA) in the blood after prostate cancer treatment.

Key features of the study:

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global diagnostic radiopharmaceuticals and contrast media market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Siemens Healthineers, Nordion Inc., Lantheus Holdings Inc., Guerbet Group, GE Healthcare, Curium, Bracco Imaging SpA, Bayer AG, Cardinal Health Inc., and NTP Radioisotopes SOC Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global diagnostic radiopharmaceuticals and contrast media market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global diagnostic radiopharmaceuticals and contrast media market.

Detailed Segmentation:

• Global Diagnostic Radiopharmaceuticals and Contrast Media Market, By Radiopharmaceuticals (Revenue, USD Mn, 2021 - 2033)
• By Type of Imaging Modality:
  • SPECT
  • PET
• By Application
  • Diagnostic application
  • Therapeutic application
• Global Diagnostic Radiopharmaceuticals and Contrast Media Market, By Contrast Media (Revenue, USD Mn, 2021 - 2033)
• By Procedure
  • X-Ray/Computed Tomography (CT)
  • Magnetic Resonance Imaging (MRI)
  • Ultrasound
• By Application
  • Cardiovascular Disease
  • Oncology
  • Gastrointestinal Disorders
  • Neurological Disorders
  • Other Indications
• Regional Insights (Revenue, USD Mn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Company Profiles:
• Siemens Healthineers
• Nordion Inc.
• Lantheus Holdings Inc.
• Guerbet Group
• GE Healthcare
• Curium
• Bracco Imaging SpA
• Bayer AG
• Cardinal Health Inc.
• NTP Radioisotopes SOC Ltd.

Table of Contents:

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Radiopharmaceuticals
  • Market Snapshot, By Contrast Media
  • Market Snapshot, By Geography
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Rise in burden of cardiovascular diseases and cancer worldwide
  • Short half-life of radiopharmaceuticals and high costs of the techniques
  • Increasing demand for image-guided procedures and diagnostics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER€(TM)s Analysis
• Merger and Acquisition Scenario

4. Global Diagnostic Radiopharmaceuticals and Contrast Media Market

• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Diagnostic Radiopharmaceuticals and Contrast Media Market, By Radiopharmaceuticals, 2021 - 2033, (US$ Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 €" 2033
  • Segment Trends
• By Type of Imaging Modality
  • SPECT
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
  • PET
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
• By Application
  • Diagnostic Application
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
  • Therapeutic Application
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)

6. Global Diagnostic Radiopharmaceuticals and Contrast Media Market, By Contrast Media, 2021 - 2033, (US$ Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 €" 2033
  • Segment Trends
• By Procedure
  • X-Ray/Computed Tomography (CT)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
  • Magnetic Resonance Imaging (MRI)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
  • Ultrasound
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
• By Application
  • Cardiovascular Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
  • Oncology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
  • Gastrointestinal Disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
  • Neurological Disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
  • Other Indications
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)

7. Global Diagnostic Radiopharmaceuticals and Contrast Media Market, By Geography, 2021 - 2033, (US$ Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 €" 2033
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Radiopharmaceuticals, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Contrast Media, 2021 - 2033,(US$ Mn)
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Radiopharmaceuticals, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Contrast Media, 2021 - 2033,(US$ Mn)
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Radiopharmaceuticals, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Contrast Media, 2021 - 2033,(US$ Mn)
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Radiopharmaceuticals, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Contrast Media, 2021 - 2033,(US$ Mn)
• Middle East & Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Radiopharmaceuticals, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Contrast Media, 2021 - 2033,(US$ Mn)

8. Competitive Landscape

• Siemens Healthineers
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Nordion Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Lantheus Holdings Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Guerbet Group
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GE Healthcare
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Curium
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bracco Imaging SpA
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bayer AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• NTP Radioisotopes SOC Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Cardinal Health Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

9. Section

• Research Methodology
• About us